PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Up 140.8% in March

PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) saw a significant increase in short interest in March. As of March 13th, there was short interest totaling 11,335 shares, an increase of 140.8% from the February 26th total of 4,707 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 5,784 shares, the short-interest ratio is currently 2.0 days.

PureTech Health Stock Performance

Shares of NASDAQ:PRTC traded down $0.68 during midday trading on Friday, reaching $15.08. The company’s stock had a trading volume of 8,316 shares, compared to its average volume of 3,800. The business’s fifty day simple moving average is $17.59 and its 200-day simple moving average is $17.29. PureTech Health has a fifty-two week low of $13.30 and a fifty-two week high of $20.00.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of PureTech Health in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On PureTech Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PRTC. Diadema Partners LP bought a new position in shares of PureTech Health in the second quarter worth about $126,000. Pentwater Capital Management LP increased its holdings in shares of PureTech Health by 50.0% in the third quarter. Pentwater Capital Management LP now owns 75,000 shares of the company’s stock valued at $1,388,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Lansdowne Partners UK LLP bought a new position in PureTech Health in the 3rd quarter worth approximately $260,973,000. Institutional investors and hedge funds own 0.04% of the company’s stock.

PureTech Health Company Profile

PureTech Health (NASDAQ: PRTC) is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.

PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.